Biovet, subsidiary of Hyderabad-based Bharat Biotech, launches vaccine for Lumpy Skin Disease
The Biolumpivaxin will help in disease surveillance to protect livestock from Lumpy Skin disease
Hyderabad: Biovet, a subsidiary of Hyderabad-based Bharat Biotech on Wednesday launched Biolumpivaxin for protecting livestock from Lumpy Skin Disease. The Biolumpivaxin is a Differentiating Infected from Vaccinated Animals (DIVA) marker vaccine, which will help in disease surveillance to protect livestock from Lumpy Skin disease (LSD), Bharat Biotech in a press release said.
Dr Krishna Ella, Founder, Biovet, and Executive Chairman of Bharat Biotech said that Biolumpivaxin is a novel indigenous live-attenuated marker vaccine developed using the LSD virus/Ranchi/2019 vaccine strain from Indian Council of Agriculture Research-National Research Centre on Equines (ICAR-NRCE), Hisar, in collaboration with Biovet.
The quality, safety, and efficacy of the vaccine has been extensively tested at Indian Council of Agriculture Research-Indian Veterinary Research Institute (IVRI) and ICAR-NRCE ensuring it meets the highest global standards. The vaccine also enables serological differentiation between naturally infected and vaccinated animals with the DIVA concept.
Biovet can produce 500 million doses of the vaccine from its production facilities in Bengaluru, ensuring sustainable supplies. The Chief Minister of Andhra Pradesh N Chandrababu Naidu, launched the indigenously developed vaccine in Vijayawada on Wednesday.
